DAAG PRESS RELEASES

MHRA review of dopamine agonist medications welcomed, with call for stronger evidence-based action

London, UK – 2 June 2026 – The Dopamine Agonist Action Group (DAAG) welcomes the MHRA’s review into dopamine agonist medications.

The group believes that current clinical guidance does not adequately reflect the evolving evidence on the risks associated with these medicines, including impulse control disorders and augmentation. As a result, there is concern that both clinicians and patients may not always be supported to make fully informed decisions or to implement appropriate monitoring and safeguarding.

DAAG notes that more recent evidence suggests a higher prevalence of impulse control disorders associated with certain dopamine agonists, including pramipexole, which may not be fully reflected in current risk classifications and clinical guidance.

The group has requested an opportunity to contribute to the MHRA consultation process, including sharing patient and clinical perspectives to support strengthened warnings, guidance, and safety monitoring. This request has been submitted directly to the MHRA and also raised via Layla Moran MP, Chair of the Parliamentary Health and Social Care Committee. Read our letter here.

Speaking on behalf of DAAG, Freddie Waite said:

“This review is welcome and an important opportunity to improve patient safety. We hope the MHRA will listen carefully to those whose lives have been profoundly affected by dopamine agonist medications, including patients and families who have experienced severe and life-altering consequences.

If this review leads to stronger warnings, better monitoring, and fewer families going through what so many have already endured, including myself, it will be a significant step in the right direction.”